–
Scientists have been searching for a reliable vaccine against malaria for decades. German pharmaceutical company BioNTech claims to have found one, thanks to its mRNA technology.
–
If it is up to BioNTech, the first clinical trial of the malaria vaccine will start at the end of 2022. The pharmaceutical company says it is working on a safe and effective mRNA vaccine that offers long-term immunity against malaria.
–
Of technology behind the malaria vaccine is known for the corona vaccines from Pfizer-BioNTech and Moderna. These are also made on the basis of mRNA, the messenger with which a cell receives instructions. An mRNA vaccine injects a piece of genetic code for the production of a harmless piece of virus protein. The immune system then attacks that protein, training it for attacks by the real virus.
–